Use of engineered bone marrow stem cells to deliver brain derived neurotrophic factor under the control of a tetracycline sensitive response element in experimental allergic encephalomyelitis.
J Neuroimmunol
; 252(1-2): 1-15, 2012 Nov 15.
Article
in En
| MEDLINE
| ID: mdl-22901507
ABSTRACT
Brain derived neurotrophic factor (BDNF) has neuroprotective properties but its use has been limited by poor penetration of the blood brain barrier. Treatment using bone marrow stem cells (BMSC) or retroviruses as vectors reduces the clinical and pathological severity of experimental allergic encephalomyelitis (EAE). We have refined the BMSC based delivery system by introducing a tetracycline sensitive response element to control BDNF expression. We have now tested that construct in EAE and have shown a reduction in both the clinical and pathological severity of the disease. Further, we looked for changes in sirtuin1 and nicotinamide phosphoribosyltransferase expression that would be consistent with a neuroprotective effect.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bone Marrow Transplantation
/
Gene Transfer Techniques
/
Brain-Derived Neurotrophic Factor
/
Stem Cell Transplantation
/
Encephalomyelitis, Autoimmune, Experimental
Type of study:
Diagnostic_studies
Limits:
Animals
Language:
En
Journal:
J Neuroimmunol
Year:
2012
Document type:
Article
Affiliation country: